Application of schisandrin B and schisandrin C in the preparation of anti-hepatic fibrosis drugs

Abstract

The invention relates to the technical field of medicine. The main characteristic components of Schisandra chinensis are lignans, which include schisandrin A, schisandrin B, schisandrin C, etc. Modern pharmacological experiments show that lignans have liver protection and anti-oxidation properties. Various pharmacological activities. The invention provides new medical applications of schisandrin B and schisandrin C components, specifically the application in the preparation of anti-hepatic fibrosis drugs. The pharmacodynamic studies of the present invention show that Schizandrin B and Schisandra C can significantly reduce the concentrations of ALT and AST in the serum of liver fibrosis model rats induced by common bile duct ligation and CCL4, improve the symptoms of liver fibrosis, and have good anti-inflammatory effects. Liver fibrosis activity, so it can be used to prepare anti-hepatic fibrosis medicine or health food.

Description

Technical field:

[0001] The invention relates to the technical field of medicine, in particular to the application of schisandrin B and schisandra C in the preparation of anti-hepatic fibrosis medicine or health food. Background technique:

[0002] Liver cirrhosis is one of the common diseases that seriously endanger human health, and the incidence rate in my country is still at a relatively high level. The pathological basis of liver cirrhosis is liver fibrosis, which is caused by various liver damage factors (such as viral hepatitis, alcoholic liver disease, certain metabolic diseases, drug and chemical poison damage, and liver parasitic diseases, etc.). Damage and inflammation, leading to the necessary pathological process of chronic liver disease developing into liver cirrhosis. Liver fibrosis is a common pathological feature of most chronic liver diseases, and it is also an important intermediate link in the further development and deterioration of chronic hepatitis an...

Examples

Embodiment 1

[0014] Example 1: Therapeutic effect of schisandrin A, schisandrin B and schisandrin C on liver fibrosis model rats with common bile duct ligation

[0015] Liver fibrosis experiment with common bile duct ligation (Xu Shuyun, Bian Rulian, Chen Xiu. Pharmacological Experimental Methodology, 3rd Edition [M]. Beijing: People's Medical Publishing House, 2002: 807). The specific method is as follows:

[0016] SD rats, male and female, 6-8 weeks old, weighing 200±10 g, were provided by the Experimental Animal Center of the Second Military Medical University of the Chinese People's Liberation Army.

[0017] Breeding room temperature 18-22 ℃, relative humidity 60%-75%, artificial mixed feed feeding.

[0018] Randomly grouped, 10 rats in each group: blank control group, model group, schisandrin A group (25mg / kg·d), schisandrin A group (50mg / kg·d), schisandrin A group (75mg / kg·d). d), Schisandra B group (25mg / kg·d), Schisandra B group (50mg / kg·d), Schisandra B group (75mg / kg·d), Schisa...

Embodiment 2

[0024] Embodiment 2: Schizandrin A, Schisandrin B, Schisandrin C on CCL 4 Rat Therapeutic Effects of an Induced Liver Fibrosis Model

[0025] CCL 4 Induced liver fibrosis model experiments (Xu Shuyun, Bian Rulian, Chen Xiu. Pharmacological Experimental Methodology, 3rd Edition [M]. Beijing: People's Medical Publishing House, 2002: 807). The specific method is as follows:

[0026] SD rats, male and female, 6-8 weeks old, weighing 200±10 g, were provided by the Experimental Animal Center of the Second Military Medical University of the Chinese People's Liberation Army.

[0027] Breeding room temperature 18-22 ℃, relative humidity 60%-75%, artificial mixed feed feeding.

[0028] Randomly grouped, 10 rats in each group: blank control group, model group, schisandrin A group (25mg / kg·d), schisandrin A group (50mg / kg·d), schisandrin A group (75mg / kg·d). d), Schisandra B group (25mg / kg·d), Schisandra B group (50mg / kg·d), Schisandra B group (75mg / kg·d), Schisandra C group (25mg / kg·...

Technical field:

[0001] The invention relates to the technical field of medicine, in particular to the application of schisandrin B and schisandra C in the preparation of anti-hepatic fibrosis medicine or health food. Background technique:

[0002] Liver cirrhosis is one of the common diseases that seriously endanger human health, and the incidence rate in my country is still at a relatively high level. The pathological basis of liver cirrhosis is liver fibrosis, which is caused by various liver damage factors (such as viral hepatitis, alcoholic liver disease, certain metabolic diseases, drug and chemical poison damage, and liver parasitic diseases, etc.). Damage and inflammation, leading to the necessary pathological process of chronic liver disease developing into liver cirrhosis. Liver fibrosis is a common pathological feature of most chronic liver diseases, and it is also an important intermediate link in the further development and deterioration of chronic hepatitis an...

Examples

Embodiment 1

[0014] Example 1: Therapeutic effect of schisandrin A, schisandrin B and schisandrin C on liver fibrosis model rats with common bile duct ligation

[0015] Liver fibrosis experiment with common bile duct ligation (Xu Shuyun, Bian Rulian, Chen Xiu. Pharmacological Experimental Methodology, 3rd Edition [M]. Beijing: People's Medical Publishing House, 2002: 807). The specific method is as follows:

[0016] SD rats, male and female, 6-8 weeks old, weighing 200±10 g, were provided by the Experimental Animal Center of the Second Military Medical University of the Chinese People's Liberation Army.

[0017] Breeding room temperature 18-22 ℃, relative humidity 60%-75%, artificial mixed feed feeding.

[0018] Randomly grouped, 10 rats in each group: blank control group, model group, schisandrin A group (25mg / kg·d), schisandrin A group (50mg / kg·d), schisandrin A group (75mg / kg·d). d), Schisandra B group (25mg / kg·d), Schisandra B group (50mg / kg·d), Schisandra B group (75mg / kg·d), Schisa...

Embodiment 2

[0024] Embodiment 2: Schizandrin A, Schisandrin B, Schisandrin C on CCL 4 Rat Therapeutic Effects of an Induced Liver Fibrosis Model

[0025] CCL 4 Induced liver fibrosis model experiments (Xu Shuyun, Bian Rulian, Chen Xiu. Pharmacological Experimental Methodology, 3rd Edition [M]. Beijing: People's Medical Publishing House, 2002: 807). The specific method is as follows:

[0026] SD rats, male and female, 6-8 weeks old, weighing 200±10 g, were provided by the Experimental Animal Center of the Second Military Medical University of the Chinese People's Liberation Army.

[0027] Breeding room temperature 18-22 ℃, relative humidity 60%-75%, artificial mixed feed feeding.

[0028] Randomly grouped, 10 rats in each group: blank control group, model group, schisandrin A group (25mg / kg·d), schisandrin A group (50mg / kg·d), schisandrin A group (75mg / kg·d). d), Schisandra B group (25mg / kg·d), Schisandra B group (50mg / kg·d), Schisandra B group (75mg / kg·d), Schisandra C group (25mg / kg·...

Images